Medable Inc. a leading provider of the end-to-end platform for digitally enabled and data-driven clinical trials, today announced it has been awarded two Fast-Track Small Business Innovation (SBIR) grants from the National Cancer Institute (NCI). The grants will provide up to $3.5 million in nondilutive research funding over the next several years.
The first award provides funding to develop TogetherCare (Track Outcomes & Guidance, Technology for Health and Effective Resources), a mobile application on a smart software system that informal caregivers will use to develop and implement home-based care for cancer survivors. This mobile application will help alleviate the cancer caregiving burden and facilitate communication with patients healthcare teams by centering the conversation around a care plan. The goal of this Fast-Track project is to develop and validate a final TogetherCare mobile app that can be immediately used in health care settings.
The ultimate aim of this project is to provide a product that promotes engagement of all stakeholders to plan for care through an integrated and dynamic care plan with resources and communication pathways for care at any stage in the cancer or other disease continuums.
The second award will fund the development of DigiBioMarC (Digital BioMarkers for Clinical Impact), a scalable and flexible cloud-based platform to capture and analyze wearable, implantable, or external device data. This platform also provides an informatics tool for automated data aggregation, integration, and machine learning algorithms. It is based on the scalable user-centered Medable platform, which implements standardization and normalization of patient-generated data to drive health insights.
This second Fast-Track project will focus on product development with an ultimate aim of a product that improves cancer research data and clinical trials, enhances clinical care, and that can be used to easily engage patients in preventive health behaviors and treatment adherence.
The SBIR program is incredibly competitive and winning these awards are another validation of Medables industry-leading, intelligent end-to-end cloud platform that provides a unified, flexible suite of tools where patients, providers, CROs and sponsors can work together as an effective clinical trial team, said Dr. Michelle Longmire, Medable CEO and co-founder. We are the only health platform company providing health prediction and precision across massive mobile app datasets, and these funds will support the development of new products that have the potential to improve patient outcomes. As a leader in global clinical trial innovation, we want to enable a transformation to better understand human health.
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable is on a mission to get effective therapies to patients faster by dramatically reducing the time from therapeutic development to market realization with digital data capture and real-time analytics that remove the complexities of clinical research to dramatically reduce trial timelines. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Our E2E platform allows patients, healthcare providers, clinical research organizations and pharmaceutical sponsors to work together as a connected and empowered team in clinical trials and research.
For more information, visit www.medable.com and follow Medable on Twitter: @Medableinc